Related Experiment Video

Updated: Jun 20, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker

Masanori Abe1, Kazuyoshi Okada, Koichi Matsumoto

  • 1Nihon University School of Medicine, Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, 30-1, Oyaguchi-Kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. mabe@med.nihon-u.ac.jp

Expert Opinion on Drug Metabolism & Toxicology
|September 19, 2009
PubMed

Insights

Fixed-dose combination therapy with losartan and hydrochlorothiazide (HCTZ) offers superior blood pressure control and improved safety over monotherapy. This combination is beneficial for hypertensive patients, potentially reducing metabolic side effects like hyperuricemia.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Antihypertensive treatment aims to decrease cardiovascular and cerebrovascular events.
  • Combination therapy often surpasses monotherapy in efficacy and safety for managing hypertension.
  • Fixed-dose combinations offer enhanced patient compliance and therapeutic outcomes.

Purpose of the Study:

  • To evaluate the benefits of fixed-dose combination therapy with losartan and hydrochlorothiazide (HCTZ).
  • To compare the efficacy and safety of losartan/HCTZ combination versus monotherapy.
  • To explore the advantages for patients with hyperuricemia.

Main Methods:

  • The study reviews existing data on fixed-dose combination therapy of losartan and HCTZ.
  • Comparative analysis of blood pressure reduction and adverse event profiles.
  • Assessment of metabolic effects, particularly concerning hyperuricemia.

Main Results:

  • Losartan plus HCTZ provides more effective blood pressure control compared to monotherapy.
  • This combination may reduce the incidence of HCTZ-induced metabolic disorders, including hyperuricemia.
  • Blood pressure reduction achieved is comparable to other antihypertensive combinations.

Conclusions:

  • Fixed-dose combination of losartan and HCTZ is an effective antihypertensive strategy.
  • It offers improved blood pressure control, a favorable safety profile, and potential benefits for metabolic health.
  • This combination is a logical therapeutic choice for patients requiring intensified blood pressure management.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...